매사추세츠의 자가면역질환 임상 시험
자가면역질환 관련 연구 16개가 매사추세츠 내 여러 지역에서 참여자를 모집하고 있습니다.
매사추세츠의 도시
공식 연구 텍스트(영어)
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- Tufts Medical Center, Boston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07621809Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT03816345A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Massachusetts General Hospital, Boston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT06722235RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
피험자 모집 중2/3상
6세 ~ 75세 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT06154252A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Massachusetts General Hospital, Boston
- University of Massachusetts Chan Medical School, Worcester
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT06948318The Mycophenolate Pregnancy Registry
- Quintiles Outcome, Cambridge
피험자 모집 중관찰 연구
전 연령 · 여성 · 2026. 9. 8. 업데이트됨 · NCT01733082RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Boston Children's Hospital, Boston
- 외 2개
피험자 모집 중1/2상
18세 ~ 65세 · 모든 성별 · 2026. 8. 26. 업데이트됨 · NCT06121297Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder
- MGH Lurie Center for Autism, Lexington
피험자 모집 중초기 1상
18세 ~ 50세 · 남성 · 2026. 8. 19. 업데이트됨 · NCT06934915RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Beth Israel Deaconess Medical Center, Boston
- University of Massachusetts Chan Medical School, Worcester
피험자 모집 중1/2상
18세 ~ 70세 · 모든 성별 · 2026. 8. 13. 업데이트됨 · NCT06359041A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- Boston Children's Cancer Center, Boston
피험자 모집 중3상
12세 이상 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT06056297Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1049, Foxborough
피험자 모집 중3상
18세 ~ 80세 · 모든 성별 · 2026. 7. 30. 업데이트됨 · NCT07039916A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Brigham And Womens Hospital, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 14. 업데이트됨 · NCT07115745A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT01351545Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
- Tufts University, Boston
- Massachusetts General Hospital, Boston
- Brigham and Women's Hospital, Boston
피험자 모집 중1상
18세 ~ 70세 · 모든 성별 · 2026. 6. 30. 업데이트됨 · NCT06201416A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- Brigham and Women's Hospital, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 5. 29. 업데이트됨 · NCT04422912Testimonials and Navigation in Rheumatology
- Brigham Women's Hospital, Boston
- University of Massachusetts Chan Medical School, Worcester
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 5. 6. 업데이트됨 · NCT06469788ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.